Regeneron Pharmaceuticals Inc (REGN)
843.60
+5.40
(+0.64%)
USD |
NASDAQ |
Nov 01, 16:00
843.60
0.00 (0.00%)
After-Hours: 20:00
Regeneron Pharmaceuticals Enterprise Value: 84.89B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 84.89B |
| October 31, 2024 | 84.30B |
| October 30, 2024 | 93.59B |
| October 29, 2024 | 94.09B |
| October 28, 2024 | 94.23B |
| October 25, 2024 | 94.72B |
| October 24, 2024 | 94.26B |
| October 23, 2024 | 95.64B |
| October 22, 2024 | 98.16B |
| October 21, 2024 | 98.84B |
| October 18, 2024 | 101.28B |
| October 17, 2024 | 102.11B |
| October 16, 2024 | 103.18B |
| October 15, 2024 | 104.12B |
| October 14, 2024 | 103.87B |
| October 11, 2024 | 104.03B |
| October 10, 2024 | 102.20B |
| October 09, 2024 | 103.65B |
| October 08, 2024 | 102.88B |
| October 07, 2024 | 101.87B |
| October 04, 2024 | 103.72B |
| October 03, 2024 | 103.91B |
| October 02, 2024 | 106.74B |
| October 01, 2024 | 107.47B |
| September 30, 2024 | 107.95B |
| Date | Value |
|---|---|
| September 27, 2024 | 107.12B |
| September 26, 2024 | 106.81B |
| September 25, 2024 | 105.84B |
| September 24, 2024 | 107.48B |
| September 23, 2024 | 112.55B |
| September 20, 2024 | 118.40B |
| September 19, 2024 | 118.97B |
| September 18, 2024 | 117.71B |
| September 17, 2024 | 118.59B |
| September 16, 2024 | 119.28B |
| September 13, 2024 | 119.31B |
| September 12, 2024 | 120.54B |
| September 11, 2024 | 118.00B |
| September 10, 2024 | 117.44B |
| September 09, 2024 | 118.37B |
| September 06, 2024 | 116.90B |
| September 05, 2024 | 119.01B |
| September 04, 2024 | 122.18B |
| September 03, 2024 | 121.02B |
| August 30, 2024 | 122.77B |
| August 29, 2024 | 122.13B |
| August 28, 2024 | 124.38B |
| August 27, 2024 | 124.65B |
| August 26, 2024 | 124.39B |
| August 23, 2024 | 124.36B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
31.27B
Minimum
Nov 04 2019
124.65B
Maximum
Aug 27 2024
70.18B
Average
66.53B
Median
Dec 08 2021
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Eli Lilly and Co | 805.11B |
| Pfizer Inc | 221.03B |
| Biogen Inc | 29.92B |
| Vertex Pharmaceuticals Inc | 115.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.341B |
| Revenue (Quarterly) | 3.721B |
| Total Expenses (Quarterly) | 2.485B |
| EPS Diluted (Quarterly) | 11.54 |
| Gross Profit Margin (Quarterly) | 86.80% |
| Profit Margin (Quarterly) | 36.03% |
| Earnings Yield | 4.79% |
| Operating Earnings Yield | 4.21% |
| Normalized Earnings Yield | 4.538 |